GRACE Phase 3 trial of relacorilant nears complete enrollment
Enrollment is nearly complete for a Phase 3 trial that is investigating the safety and effectiveness of relacorilant in people with Cushing’s syndrome due to any underlying cause, according to a corporate update from its developer, Corcept Therapeutics. The trial, called GRACE (NCT03697109), is enrolling about 130 people…